See more : Celcuity Inc. (CELC) Income Statement Analysis – Financial Results
Complete financial analysis of Lexston Life Sciences Corp. (LEXTF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lexston Life Sciences Corp., a leading company in the Biotechnology industry within the Healthcare sector.
- Cykel AI PLC (CYK.L) Income Statement Analysis – Financial Results
- MRT Inc. (6034.T) Income Statement Analysis – Financial Results
- Ascent Industries Co. (ACNT) Income Statement Analysis – Financial Results
- Winland Holdings Corporation (WELX) Income Statement Analysis – Financial Results
- abrdn Private Equity Opportunities Trust plc (APEO.L) Income Statement Analysis – Financial Results
Lexston Life Sciences Corp. (LEXTF)
About Lexston Life Sciences Corp.
Lexston Life Sciences Corp. operates as a biotechnology company that provides cannabis testing and research services in Canada. The company also offers analytical testing for cannabis, pathogens, and toxins. In addition, it focuses on developing and validating methods for standardized manufacturing of plant derived psychedelics in the field of mental health and wellness. The company is based in Vancouver, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 361.01K | 149.11K | 0.00 |
| Cost of Revenue | 26.39K | 29.80K | 119.52K | 89.01K | 0.00 |
| Gross Profit | -26.39K | -29.80K | 241.49K | 60.10K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 66.89% | 40.31% | 0.00% |
| Research & Development | 0.00 | 19.17K | 125.45K | 43.20K | 0.00 |
| General & Administrative | 424.99K | 568.17K | 1.64M | 493.70K | 0.00 |
| Selling & Marketing | 102.70K | 172.90K | 303.25K | 3.02K | 0.00 |
| SG&A | 674.72K | 871.53K | 1.95M | 496.72K | 6.48K |
| Other Expenses | 0.00 | 0.00 | 31.98K | 0.00 | 0.00 |
| Operating Expenses | 674.72K | 871.53K | 2.11M | 551.19K | 6.48K |
| Cost & Expenses | 674.72K | 871.53K | 2.22M | 640.20K | 6.48K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 26.39K | 29.80K | 31.98K | 11.27K | 171.86K |
| EBITDA | -648.32K | -841.73K | -1.89M | -479.82K | -6.48K |
| EBITDA Ratio | 0.00% | 0.00% | -380.91% | -63.56% | 0.00% |
| Operating Income | -674.72K | -871.53K | -1.86M | -106.04K | -6.48K |
| Operating Income Ratio | 0.00% | 0.00% | -516.23% | -71.12% | 0.00% |
| Total Other Income/Expenses | -59.56K | -94.54K | -320.59K | -385.04K | -3.00 |
| Income Before Tax | -734.28K | -966.07K | -2.32M | -876.13K | -6.48K |
| Income Before Tax Ratio | 0.00% | 0.00% | -642.70% | -587.57% | 0.00% |
| Income Tax Expense | 0.00 | 142.68K | 456.56K | 385.04K | -171.86K |
| Net Income | -867.71K | -1.11M | -2.32M | -876.13K | -6.48K |
| Net Income Ratio | 0.00% | 0.00% | -642.70% | -587.57% | 0.00% |
| EPS | -0.02 | -0.03 | -0.21 | -0.09 | 0.00 |
| EPS Diluted | -0.03 | -0.04 | -0.21 | -0.09 | 0.00 |
| Weighted Avg Shares Out | 37.69M | 32.80M | 11.16M | 9.99M | 9.99M |
| Weighted Avg Shares Out (Dil) | 31.89M | 28.58M | 11.16M | 9.99M | 9.99M |
Source: https://incomestatements.info
Category: Stock Reports